J8565 Gefitinib oral
Also known as: Iressa, Oral gefitinib
Gefitinib administered orally; a tyrosine kinase inhibitor targeting epidermal growth factor receptor used for non-small cell lung cancer.
In Plain Language
Lung cancer treatment pill; Targeted cancer therapy
Clinical Context
Used for non-small cell lung cancer with EGFR mutations. Oral tyrosine kinase inhibitor with good CNS penetration.
RVU Information
CPT J8565 does not have a physician work RVU assigned by CMS. This is typical for supply, drug, and equipment codes — reimbursement is based on Average Sales Price (ASP), fee schedules, or payer contracts rather than the RVU system.
Billing & Documentation
J-codes represent drugs administered by a healthcare provider (not self-administered). Documentation must include the drug name, dosage, route of administration, and medical necessity. Most payers require the National Drug Code (NDC) on the claim. Bill the appropriate administration code (96365-96379) in addition to the drug code.
Specialties
Frequently Asked Questions
What is CPT code J8565?
CPT J8565 (Gefitinib oral) is a J Codes (Drugs) code. Gefitinib administered orally; a tyrosine kinase inhibitor targeting epidermal growth factor receptor used for non-small cell lung cancer.
How is J8565 administered?
CPT J8565 is administered by a healthcare provider, typically via injection or infusion. Used for non-small cell lung cancer with EGFR mutations. Oral tyrosine kinase inhibitor with good CNS penetration. It is used by Oncology, Pulmonology, Internal Medicine.
When is CPT J8565 used?
Used for non-small cell lung cancer with EGFR mutations. Oral tyrosine kinase inhibitor with good CNS penetration.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against MGMA data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.